1/30/2023 7:42:19 AM
Zai Lab Announces NDA For Sulbactam-Durlobactam Granted Priority Review By China’s NMPA
1/9/2023 7:47:45 AM
Zai Lab Appoints Michel Vounatsos To Board
1/5/2023 8:09:53 AM
Zai Lab And Novocure Announce Pivotal LUNAR Study In NSCLC Meets Primary Overall Survival Endpoint
4/4/2022 11:01:46 AM
1&1 Mobilfunk And GfTD GmbH Sign Contract For Construction Of Antenna Sites In German
2/17/2022 8:08:11 AM
Zai Lab Announces Breakthrough Therapy Designation Granted For Repotrectinib In China
1/12/2022 7:37:32 AM
Zai Lab Announces First Patient Treated In Greater China In PANOVA-3 Phase 3 Pivotal Trial
11/30/2021 7:34:13 AM
Zai Lab Announces Positive Topline Results From Phase 3 PRIME Study Of ZEJULA
11/22/2021 7:33:31 AM
Zai Lab Appoints Richard Gaynor To Board
11/11/2021 7:38:16 AM
Zai Lab Doses First Patient In Greater China In Global Registrational Clinical Trial Of Efgartigimod
11/9/2021 8:11:16 AM
Blueprint Medicines, Zai Lab Unveil Collaboration And License Deal For BLU-945 And BLU-701 In Greater China
11/9/2021 7:43:37 AM
Karuna And Zai Lab Collaborate For Development, Manufacturing, And Commercialization Of KarXT In Greater China
10/18/2021 7:43:44 AM
Zai Lab Appoints Scott Morrison To Board
10/4/2021 7:50:06 AM
Novocure, Zai Lab Announce Last Patient Enrolled In Phase 2 Pilot Trial Of Tumor Treating Fields Plus Chemotherapy
9/14/2021 7:39:01 AM
Zai Lab Announces Breakthrough Therapy Designation Granted For Bemarituzumab In China